[Interleukin-2 modifies the development of insulin-dependent diabetes of BB rats].
Intraperitoneal administration of human recombinant IL-2 led to a significant, dose-dependent increase and acceleration of diabetes development in BB rats, while we observed a suppression of diabetes development in animals with a high spontaneous disease incidence.
Zielasek
J
J
Klinische Abteilung des Diabetes-Forschungsinstituts, Universität Düsseldorf.
Burkart
V
V
Kolb
H
H
D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000276:immunology*; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D007274:Injections, Intraperitoneal; D007376:Interleukin-2 / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D011913:Rats, Inbred BB; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology
D007376:Interleukin-2; D011994:Recombinant Proteins
Interleukin-2 beeinflusst die Entwicklung des insulinpflichtigen Diabetes der BB-Ratte.